Alar Pharmaceuticals Company Description

Alar Pharmaceuticals Inc., a drug development company, focuses on developing long-acting release drug products for CNS disorders and chronic diseases in Taiwan.

It is developing ALA-1000, which is in Phase II clinical trials for the treatment of opioid use disorder; ALA-1300 and ALA-2000, which is in pre-clinical stage for opioid use disorder; ALA-4000 which is in pre-clinical stage for treatment of Parkinson’s disease; and ALA-3000, which is in pre-clinical stage for treating treatment-resistant depression.

Alar Pharmaceuticals Inc. was founded in 2016 and is based in Taichung, Taiwan.

Alar Pharmaceuticals Inc.

Country	Taiwan
Founded	2016
Industry	Drug Manufacturers - Specialty & Generic
Sector	Healthcare
Employees	22
CEO	Yung-Shun Wen

Contact Details

Address: No. 32, Keya Road Taichung Taiwan
Phone	886 4 2463 7115
Website	alarpharm.com

Stock Details

Ticker Symbol	6785
Exchange	Taipei Exchange
Fiscal Year	January - December
Reporting Currency	TWD
SIC Code	2834

Key Executives

Name	Position
Dr. Yung-Shun Wen Ph.D.	Chief Executive Officer and Director
Vivian Kang	Director of Finance